ADAM8 Antibody [Unconjugated]

ADAM8 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Goat Anti-Human ADAM8 Ectodomain Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1031) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasmic. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

• Reactivity: Hu
• Applications: WB, IP, ICC/IF
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

ADAM8 Antibody [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human ADAM8 Ectodomain
  Glu158-Ser653
  Accession # P78325
• Specificity: Detects human ADAM8 Ectodomain in direct ELISAs and Western blots. In direct ELISAs, approximately 50% cross-reactivity with recombinant mouse ADAM8 is observed and less than 1% cross-reactivity with recombinant human (rh) ADAM12, rhADAM19, and rhADAM33 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: ADAM8
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 5-15 ug/mL
  • Immunoprecipitation 25 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ADAM8 Antibody [Unconjugated]

• a disintegrin and metalloproteinase domain 8
• ADAM 8
• ADAM metallopeptidase domain 8
• ADAM8
• CD156a antigen
• CD156a
• CD156human leukocyte differentiation antigen
• Cell surface antigen MS2
• EC 3.4.24
• EC 3.4.24.-
• MGC134985
• MS2
• MS2disintegrin and metalloproteinase domain-containing protein 8

Background

ADAM8, also known as cell surface antigen MS2 or CD156a, is a member of the ADAM family that contains a disintegrin and metalloprotease-like domain (1, 2). ADAM8 can cleave a variety of substrates and has been shown as a sheddase for the low affinity IgE receptor CD23 and the neural recognition molecule CHL1 (3, 4). Expression and regulation studies suggest that ADAM8 is a novel osteoclast stimulating factor and may play a role in asthma (5, 6). The 824 amino acid precursor of human ADAM8 consists of a signal peptide (residues 1 to 16), a pro peptide (residues 17 to 199), a metaloprotease domain (residues 200 to 400), a disintegrin-like domain (residues 408 to 494), a cysteine-rich region (residues 497 to 613), an EGF-like domain (residues 614 to 640), a transmembrane region (residues 656 to 676) and a cytoplasmic domain (residues 677 to 824).

1. Yoshiyama, K. et al. (1997) Genomics 41:56.
2. Moss, M.L. and J.W. Bartsch (2004) Biochemistry 43:7227.
3. Fourie, A.M. et al. (2003) J. Biol. Chem. 278:30469.
4. Naus, S. et al. (2004) J. Biol. Chem. 279:16083.
5. Choi, S.J. et al. (2001) J. Bone Miner. Res. 16:814.
6. King, N.E. et al. (2004) Am. J. Respir. Cell Mol. Biol. 31:257.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for ADAM8 Antibody (AF1031)(10)

Publications using AF1031

• Mineva, ND;Pianetti, S;Das, SG;Srinivasan, S;Billiald, NM;Sonenshein, GE; A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer Pharmaceutics 2024-04-13 [PMID: 38675197] (Flow Cytometry, N/A)
• Mi, Z;Kuo, MC;Kuo, PC; RNA Aptamer Targeting of Adam8 in Cancer Growth and Metastasis Cancers 2023-06-20 [PMID: 37370863] (Neutralization, Human)
• C Conrad, D Yildiz, SJ Cleary, A Margraf, L Cook, U Schlomann, B Panaretou, JL Bowser, H Karmouty-Q, J Li, NK Berg, SC Martin, A Aljohmani, SF Moussavi-H, KM Wang, JJ Tian, M Magnen, C Valet, L Qiu, JP Singer, HK Eltzschig, CAPSys Stu, W Bertrams, S Herold, N Suttorp, B Schmeck, ZT Ball, A Zarbock, MR Looney, JW Bartsch ADAM8 signaling drives neutrophil migration and ARDS severity JCI Insight, 2022-02-08;7(3):. 2022-02-08 [PMID: 35132956] (Flow Cytometry, ICC, IHC, Human)
• C Jaworek, Y Verel-Yilm, S Driesch, S Ostgathe, L Cook, S Wagner, DK Bartsch, EP Slater, JW Bartsch Cohort Analysis of ADAM8 Expression in the PDAC Tumor Stroma Journal of personalized medicine, 2021-02-10;11(2):. 2021-02-10 [PMID: 33578644] (IHC, Human)
• Yu Li, Songbo Guo, Kai Zhao, Catharina Conrad, Caroline Driescher, Vanessa Rothbart et al. ADAM8 affects glioblastoma progression by regulating osteopontin-mediated angiogenesis Biological Chemistry 1/27/2021 [PMID: 33544472]
• K Theodorou, EPC van der Vo, MJ Gijbels, IMJ Wolfs, M Jeurissen, TL Theelen, JC Sluimer, E Wijnands, JP Cleutjens, Y Li, Y Jansen, C Weber, A Ludwig, JF Bentzon, JW Bartsch, EAL Biessen, MMPC Donners Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression Sci Rep, 2017-09-15;7(1):11670. 2017-09-15 [PMID: 28916789] (IHC, Human)
• Daniela Dreymueller, Jessica Pruessmeyer, Julian Schumacher, Sandra Fellendorf, Franz Martin Hess, Anke Seifert et al. The metalloproteinase ADAM8 promotes leukocyte recruitment in vitro and in acute lung inflammation American Journal of Physiology-Lung Cellular and Molecular Physiology 9/1/2017 [PMID: 28596294]
• Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia A, Hofling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem R, Moss M, Rasmussen F, Miller M, Lauffenburger D, Tuveson D, Nimsky C, Bartsch J ADAM8 as a drug target in pancreatic cancer. Nat Commun, 2015-01-28;6(0):6175. 2015-01-28 [PMID: 25629724] (Immunoprecipitation, Native SDS-PAGE, Human)
• Nancy Ruel, Dessislava Z. Markova, Sherrill L. Adams, Carla Scanzello, Gabriella Cs-Szabo, David Gerard et al. Fibronectin Fragments and the Cleaving Enzyme ADAM-8 in the Degenerative Human Intervertebral Disc Spine (Phila Pa 1976) 7/15/2014 [PMID: 25010013]
• Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, Martin C, Premachandra DJ, Okada Y, Peltonen J, Grenman R, James HA, Edwards DR, Kahari VM Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin. Cancer Res., 2010-03-21;16(0):2022. 2010-03-21 [PMID: 20305301] (Western Blot, Human)

Reviews for ADAM8 Antibody (AF1031) (2)

Average Rating: 4

(Based on 2 reviews)

We have 2 reviews tested in 1 species: Human.

reviewed by: Verified Customer IHC-Fr Human 01/27/2015

Summary

• Application: Immunohistochemistry-Frozen
• Sample Tested: Human intervetebral disc nucleus pulposus
• Species: Human
• Lot: FUU01

reviewed by: Verified Customer IHC-P Human 01/05/2015

Summary

• Application: Immunohistochemistry-Paraffin
• Sample Tested: See PMID 23101757
• Species: Human

Bioinformatics

• Gene Symbol: ADAM8
• Uniprot:
  • P78325()